All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
ASCT in DLBCL – is it over?
Featured:
Ulrich Jäger
Grzegorz Nowakowski
Michael Dickinson
Catherine Thieblemont
Gilles Salles
Astrid Pavlovsky
Judith Trotman
Andrew DaviesAs part of our biannual steering committee meeting, Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, USA, chaired a discussion session on the current and future role of autologous stem cell transplant in the treatment of diffuse large B-cell lymphoma. Many steering committee members felt that this therapy no longer plays an important role in treatment of the disease.
ASCT in DLBCL – is it over?
ASCT in DLBCL – is it over?
Your opinion matters
What types of support services or resources do you think would best facilitate the safe implementation of the BrECADD regimen in clinical practice?